Heraeus

ADVANCING, TOGETHER more than





PALACOS®R+G

PALACOS®R+G SIMPLY UNIQUE



ORIGINAL: The Unique Palacos® Polymers¹

- Exclusive expertise: polymers are the most important basic component¹ of bone cement and determine its final properties
- Unique polymers are the basis for the performance of PALACOS[®]



IT'S ALL IN THE MIX: THE UNIQUE PALACOS® FORMULATION¹

- The exact composition is crucial¹
- The original formulation of PALACOS® R+G is unique



FOR OVER 50 YEARS: THE UNIQUE PALACOS® PRODUCTION

- Attention to detail and experience spanning decades: high production standards
- Made in Germany for the whole world



LONG-LASTING STABILITY^{2,3}

- Highly resistant due to special material properties⁴
- Optimum interlock with the bone thanks to ideal intrusion depth⁵⁻⁷

EFFECTIVE LOCAL ANTIBIOTIC RELEASE⁸

 Local protection for the implant area: the released antibiotic gentamicin is effective against a wide range of germs⁹

G

 2 to 3 times higher antibiotic release compared to other bone cements due to the unique PALACOS[®] polymers⁸

LONG IMPLANT SURVIVAL^{10,11}

Real-world data from the world's largest arthroplasty registry¹²



fewer revisions

in hip surgeries with PALACOS[®] R+G compared to other bone cements¹⁰

17%

fewer revisions

in knee surgeries with PALACOS[®] R+G compared to other bone cements¹¹

... AND SATISFIED PATIENTS^{13, 14,*}



following knee surgeries with PALACOS® R+G compared to other bone cements^{13,*}



of patients describe the result of their hip surgeries with PALACOS® R+G as

"good, very good or excellent"^{14,*}

PALACOS® PROVEN RELIABILITY



I like the consistency of this cement, which always tells me which stage of the process it is in. With this cement you already know by feel what kind of strength it develops, when it will be ready, when you have to stop mixing.

A. Seitz, medius clinics, Germany

I believe that an implant is only as good as the bond between the cement and the bone. If the bond is not good enough, the whole procedure will fail. The choice of bone cement is connected to the implant survival. Dr. C. H. Geerdink, Ikazia Hospital, Netherlands

What makes PALACOS[®] R+G so special is the consistency and reliability. In the operating room, it seems like every day there's something different. To have something be there that you can trust and rely on in each case, I think is really important for the excellent outcomes for the patient. Dr. M. Dietz, West Virginia University, USA



PALACOS[®] Advancing, together

PALACOS[®] R+G is the world's first antibiotic-loaded bone cement for use in arthroplasty and the leader in clinical evidence.¹⁵ For over 50 years, this bone cement has been synonymous with a higher quality of life for patients and is considered the gold standard today. This success relies on a wide range of people working together. PALACOS[®] R+G is our mutual success story.



Thank you for decades of trusted collaboration for best patient outcomes. Trusting in PALACOS® means trusting in clinical evidence.

1. Kuehn KD, PMMA Cement Composition and Chemistry. In: Kuehn KD, eds. PMMA Cement. Springer Verlag 2014; 71–92 (in vitro). | 2. Furnes O, Havelin L, Espehaug B. Properties of bone cement – which cement should we choose for primary THA? In: Breusch S, Malchau H, eds. The Well-Cemented Total Hip Arthroplasty. Springer Verlag 2005; 103 ff. 1 3. Espehaug B, Furnes O, Havelin L, Engesæter L, Vollset S. The type of cement and failure of total hip replacements. J Bone Joint Surg 2002; 84-B: 832–883. | 4. Data on file (in vitro). | 5. Espehaug B, Furnes O, Engesaeter L, Havelin L. 18 years of results with cemented primary hip prostheses in the Norwegian Arthroplasty Register: concerns about some newer implants. Acta Orthop Scand 2009; 80 (4); 402–412. | 6. Vanlommel J. Cementing the Tibial Component in Total Knee Arthroplasty. J Arthroplasty 2011; 26 (3): 492–496 (in vitro). | 7. Kuehn KD, Novel Comparative Data. In: Kuehn KD, eds. PMMA Cement. Springer Verlag 2014; 214–215 (in vitro). | 8. Zimmerli W. From Microbiology to Diagnostics and Treatment. In: Zimmerli W. Bone and Joint Infections. Wiley Blackwell 2015; 132 (in vitro). | 9. Kuehn KD, PMMA Cement. S0/2022. Revision and Survivorship – page 10. Current reports accessible at http://herae.us/njr-data. | 11. NIR Implant Summary Report for Heraeus Medical GmbH. Primary Hips using PALACOS® Antibiotic Cement: 08/2022. Revision and Survivorship – page 6. Current reports accessible at http://herae.us/njr-data. | 12. NIR Teport 202: Surgical data to 31 December 2021; 3. | 13. NIR Implant Summary Report for Heraeus Medical GmbH. Primary Knees using PALACOS® Antibiotic Cement: 08/2022. Patient Reports accessible at http://herae.us/njr-data. | 14. NIR Implant Summary Report for Heraeus Medical GmbH. Primary Knees using PALACOS® Antibiotic Cement: 08/2022. – page 8. Current reports accessible at http://herae.us/njr-data. | 14. NIR Implant Summary Report for Heraeus Medical GmbH. Primary Knees using PALACOS® Antibiotic Cement: 08/2022. – page 8. Current reports accessible at

www.heraeus-medical.com



We thank the patients and staff of all the hospitals in England, Wales, Northern Ireland and the Isle of Man who have contributed data to the National Joint Registry. We are grateful to the Healthcare Quality Improvement Partnership (HQIP), the NJR Steering Committee and staff at the NJR Centre for facilitating this work. The views expressed represent those of Heraeus Medical GmbH and do not necessarily reflect those of the National Joint Registry Steering Committee or the Health Quality Improvement Partnership (HQIP) who do not vouch for how the information is presented.